Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia

Recent studies suggest that JAK2 serves as a novel therapeutic target in Bcr-Abl+ chronic myelogenous leukemia (CML). We have reported the existence of an HSP90- associated high molecular weight network complex (HMWNC) that is composed of HSP90 client proteins BCR-ABL, JAK2, and STAT3 in wild type B...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Sandip N., Leng, Xiaohong, Perazzona, Bastianella, Sun, Xiaoping, Lin, Yu-Hsi, Arlinghaus, Ralph B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979592/
https://www.ncbi.nlm.nih.gov/pubmed/27551334
http://dx.doi.org/10.18632/genesandcancer.111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979592/
https://www.ncbi.nlm.nih.gov/pubmed/27551334
http://dx.doi.org/10.18632/genesandcancer.111

Ejemplares similares